BioChem Solutions, “INC” (“the Company” ) is a Florida company that provides treatment technologies for viral, fungal, bacterial and protozoal diseases and health conditions, particularly HIV/AIDS and Rheumatoid Arthritis, based on a patented technology invented by James Herman, BS Chemistry.

The Company’s lead therapeutics are Alphamir TM, as a prescription-only medicine to combat HIV/AIDS, and ArthromirTM for Rheumatoid Arthritis. Both of these inventions utilize Trioxolane derivatives that, upon introduction to the body’s aqueous ambience, reduce and produce high-energy oxygen metabolites within the blood stream as well as activate certain receptor cells in the oropharyngeal cavity. These receptor cells cause the body to produce CD4 cells that are the precursor cells to the evolvement of lymphocytes, and thereby modulate the natural immune process in the body.

On May 24th, 2001, the Company received provisional two-year registrations for use of AlphamirTM as a prescription-only medicine to combat HIV/AIDS and for ArthromirTM for Rheumatoid Arthritis. The two-year registrations are renewed in five-year intervals. These approvals came after completing clinical trials at the Kenya Medical Research Institute. BioChem Solutions has provided updated clinical data to the Pharmacy Poisons Board at the one-year anniversary in May 2002. These approvals allow the resultant medicines to be used as ethical drugs in 21 sub-Saharan African countries that are members of the East African Medical Conference.

On June 24, 2006 BioChem incorporate Molecular Technologies Ltd. Nairobi Africa, a wholly owned subsidiary. On June 27, 2006 the Pharmacy Poisons Board granted Molecular Technologies Ltd. an extension of the provisional registration to allow BioChem to carryout the phase III clinical trials of its product at the Kenya Medical Research Institute.

Alphamir is a safe and non-toxic substance. The safety profile was performed over a period of 6 years between 1988 and 1994 in four laboratories located in the United States, Cuba, and Kenya. Three of the facilities were medical academic institutions (University of California at Irvine, Kenya Medical Research Institute, and University of Cuba, LaHabana) and the fourth was a professional contract research organization located in California. Nineteen different safety and toxicity studies were performed including: minimum inhibition concentration assays, minimum bacterial concentration assays, acute systemic toxicity, dermal toxicity, oral toxicity, ocular irritation, primary skin irritation, vaginal and rectal irritation, AMES mutagenesis assays, micronuclei in mouse bone marrow, and other topical studies were performed in order to substantiate the effectiveness, safety, and tolerability of AlphamirTM. Of these nineteen studies, a total of 312 mice, 65 rats, and 70 rabbits were used in order to substantiate the safety of the product.

Alphamir and Arthromir's clinical investigator is Davy Kiprotich Koech BSc, MS, PhD, Cbiol, MIBiol, FinstPM, SS, CuD (Hon.), OGW. For the past 14 years, Dr. Davy Koech has served as Chief Research Officer and Director of the Kenya Medial Research Institute (KEMRI). He is the author of 161 refereed journal publications in the fields of Leishnamiasis, Schistosomiasis, Malaria, AIDS, and numerous other diseases. Research physicians, under Dr. Koech’s direction, conducted anecdotal, Phase I, and Phase II HIV/AIDS and Rheumatoid Arthritis studies which were completed at KEMRI on a total of 176 patients. From 1992-1993 a Phase I double blind clinical trial with 30 patients; 3 study arms with 10 patients each – Oropharyngeal, Suppository, and Control was performed for AIDS. The immunological results were: CD4+ lymphocyte levels in groups treated with AlphamirTM increased 100+% versus 0% change for the control group. From 1999 - 2001 the AIDS Phase II Open label clinical trial with randomized dose ranging for efficacy, safety and tolerability of AlphamirTM was performed with 43 patients which consisted of 3 study arms at buccal dose levels of Group 1 - 100 mg, Group 2 - 200 mg, and Group 3 - 400 mg. Results from Group 1 showed consistent and steady rise in weight; 50% of patients showed significant rise in CD4+ count with 33% drop in viral load. The successful results led both drugs to provisional fast tract registrations as a prescription medicine for ethical use with continued research efforts. Follow-up continues with monthly viral loads and no adverse effects encountered. Funds are needed to begin Phase III clinical trials administering Alphamir as monotherapy and in combination therapy with other drugs/therapies.

The Company will simultaneously focus its attention on significant distribution of Alphamir TM for HIV/AIDS and Arthromir TM for Rheumatoid Arthritis in Africa at very low costs while it looks to promote its products with a pharmaceutical partner in developed markets. IT suggests that the only viable and effective approach to contain HIV/AIDS must include a comprehensive program to:
1) administer a low-cost self-testing procedure which we will co-market;
2) treat infected HIV/AIDS population with Alphamir; and
3) administer a vaginal gel for the prevention of transmission which we are developing.
The demand for the use of this treatment strategy is great enough to support incrementally larger requirements of funding. At this time, we are actively pursuing funds for Phase III clinical trials, to execute this treatment strategy, and manufacture and distribute the products. It should be noted that the best scientific evidence supports the fact that viral strains cannot develop resistance to Alphamir TM and this represents a major breakthrough in the ability to effectively control the AIDS pandemic.

IT is taking an integrated approach with a cost effective treatment program. Estimates to treat the current 42 million plus infected people range from approximately $316 to $3,325 per year using presently available Highly Active Antiretroviral Treatment (HAART). In addition, the cost of the medical infrastructure for distribution, monitoring and training necessary for use of these treatment programs is prohibitive throughout Africa. IT is launching Alphamir TM with a cost of $205 per year per patient for an orally prescribed medication not requiring water to swallow. Efforts are being made to bring those costs down substantially for Third World countries. The dosage of 100 mg, 4 times a day (10 drops/25 mg under the tongue 4 times) is expected to be available in tablet form that melts in the mouth without water.

The Company’s proprietary technology is unique and is closely guarded. The technology is protected by existing and future pending patents. The process and use of Trioxolane is patented in the U.S.A., Mexico, and Canada. Its use will offer the production of ethical drugs that will be further tested in clinical trials for the treatment of viral, bacterial, and fungal diseases. Subsequent patents are to be issued and will cover our invention internationally.